Repositioning Candidate Details

Candidate ID: R0913
Source ID: DB05993
Source Type: investigational
Compound Type: small molecule
Compound Name: PRX-07034
Synonyms: --
Molecular Formula: C21H29Cl2N3O4S
SMILES: Cl.COC1=C(OC)C(=CC(Cl)=C1)C(C)NC1=CC(=CC=C1S(C)(=O)=O)N1CCNCC1
Structure:
DrugBank Description: --
CAS Number: 903580-39-2
Molecular Weight: 490.44
DrugBank Indication: Investigated for use/treatment in alzheimer's disease, obesity, and schizophrenia and schizoaffective disorders.
DrugBank Pharmacology: --
DrugBank MoA: PRX-07034 is a novel, highly selective, small-molecule antagonist of a specific G-protein coupled receptor (GPCR) known as 5-HT6 being developed for the treatment of obesity, Alzheimer's disease and cognitive impairment associated with schizophrenia. PRX-07034 has also been shown to enhance cognitive function in preclinical animal models of memory impairment through a dual mechanism of action.It has an effect on both the acetylcholine and glutamate neurotransmitter systems in the brain, which makes it a potentially complementary therapy to cholinesterase inhibitors, a class of drugs approved for the treatment of Alzheimer's disease.
Targets: 5-hydroxytryptamine receptor 6
Inclusion Criteria: Therapeutic strategy associated